OOP costs high among Medicare beneficiaries with cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.670, 2013-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

National trends in pancreatic cancer outcomes and pattern of care among Medicare beneficiaries, 2000 through 2010

By Wang Yun Schrag Deborah Brooks Gabriel A. Dominici Francesca

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1050-1058

Blackwell Publishing

Access to resources Recommend Favorite

Challenges in Merging Medicaid and Medicare Databases to Obtain Healthcare Costs for Dual-Eligible Beneficiaries: Using Diabetes as an Example

By Prela Cecilia M.

PharmacoEconomics, Vol. 27, Iss. 2, 2009-01 ,pp. : 167-177

Adis International

Access to resources Recommend Favorite

Olanzapine vs risperidone costs among US Medicaid beneficiaries

Inpharma, Vol. 1, Iss. 1396, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Obama to reduce Medicare costs

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 672, 2013-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Etanercept or infliximab: costs to US Medicare

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 276, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite